Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    19091000 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Davunetide (AL-108) in Predicted Tauopathies - Pilot Study
Conditions: Predicted Tauopathies, Including:;   Progressive Supranuclear Palsy;   Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17;   Corticobasal Degeneration Syndrome;   Progressive Nonfluent Aphasia
Interventions: Drug: davunetide (AL-108, NAP);   Drug: Placebo nasal spray

Indicates status has not been verified in more than two years